BioXcel Therapeutics (BTAI) Interest & Investment Income (2018 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly Interest & Investment Income of $211000.0 in Q1 2026, down 34.27% quarter-over-quarter from $321000.0 in Q4 2025, and down 24.37% on a YoY basis from $279000.0 in Q1 2025.
BioXcel Therapeutics (BTAI) Interest & Investment Income (2018 - 2026) Analysis & Trends
BioXcel Therapeutics' Interest & Investment Income history runs 9 years deep, the most recent figure standing at $211000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 24.37% year-over-year to $211000.0; the TTM figure through Mar 2026 stood at $998000.0 (down 48.4% YoY), while the FY2025 annual figure was $1.1 million, down 59.03% from the prior year.
- Interest & Investment Income was $211000.0 for Q1 2026 at BioXcel Therapeutics, down from $321000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2.0 million in Q1 2023 to a low of $15000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $709235.3 across 5 years, with a median of $616000.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 82200.0% in 2022, then tumbled 70.54% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $1.5 million in 2022, then plunged by 36.34% to $946000.0 in 2023, then plunged by 61.1% to $368000.0 in 2024, then slipped by 12.77% to $321000.0 in 2025, then slumped by 34.27% to $211000.0 in 2026.
- The last three Interest & Investment Income figures came in at $211000.0 (Q1 2026), $321000.0 (Q4 2025), and $236000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 41.80 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 28.10 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 8.54 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 4.97 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | BioXcel Therapeutics | 25.81 Mn | 25.81 Mn | -77,000.00 | 211,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 211,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 230,000.00 |
| Mar 31, 2025 | 279,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Sep 30, 2024 | 616,000.00 |
| Jun 30, 2024 | 671,000.00 |
| Mar 31, 2024 | 947,000.00 |
| Dec 31, 2023 | 946,000.00 |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 823,000.00 |
| Jun 30, 2022 | 204,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 46,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 10,000.00 |